177 related articles for article (PubMed ID: 11158013)
1. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
2. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
[TBL] [Abstract][Full Text] [Related]
3. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.
Moller L; Norrelund H; Jessen N; Flyvbjerg A; Pedersen SB; Gaylinn BD; Liu J; Thorner MO; Moller N; Lunde Jorgensen JO
J Clin Endocrinol Metab; 2009 Nov; 94(11):4524-32. PubMed ID: 19820031
[TBL] [Abstract][Full Text] [Related]
4. Ghrelin drives GH secretion during fasting in man.
Muller AF; Lamberts SW; Janssen JA; Hofland LJ; Koetsveld PV; Bidlingmaier M; Strasburger CJ; Ghigo E; Van der Lely AJ
Eur J Endocrinol; 2002 Feb; 146(2):203-7. PubMed ID: 11834429
[TBL] [Abstract][Full Text] [Related]
5. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
6. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
[TBL] [Abstract][Full Text] [Related]
7. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
8. Effects of free fatty acids, growth hormone and growth hormone receptor blockade on serum ghrelin levels in humans.
Gormsen LC; Nielsen C; Gjedsted J; Gjedde S; Vestergaard ET; Christiansen JS; Jørgensen JO; Møller N
Clin Endocrinol (Oxf); 2007 May; 66(5):641-5. PubMed ID: 17492951
[TBL] [Abstract][Full Text] [Related]
9. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
10. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone receptor antagonist treatment reduces exercise performance in young males.
Goto K; Doessing S; Nielsen RH; Flyvbjerg A; Kjaer M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3265-72. PubMed ID: 19549743
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
15. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
16. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
[TBL] [Abstract][Full Text] [Related]
17. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
[TBL] [Abstract][Full Text] [Related]
20. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
